Amoeba stock has significantly advanced this Thursday morning, trading at 1.008 euros, marking a 3.7% increase from the previous day. The stock of the Lyon-based company, specializing in biocontrol, thus exceeds the symbolic threshold of 1 euro, amid a bullish trend that has been developing over several weeks.
Having settled at 1.008 euros, Amoeba is now trading above all its key moving averages: the 50-day moving average is at 0.96 euros, and the 200-day moving average is at 0.98 euros. This dual crossover is a closely watched technical signal, as it indicates a reversal of the medium and long-term trend in favor of buyers. The stock had fluctuated below these levels for much of the past few months. The Relative Strength Index (RSI), which measures the relative strength of the ongoing movement, stands at 62, a level that reflects buying pressure without signaling an overbought zone. The stock is also positioned above its upper Bollinger band (0.98 euros), which may indicate a short-term acceleration of the bullish movement. The main resistance threshold identified at 0.98 euros has been clearly surpassed during this session.
Recent Performance Overview
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over the past week, Amoeba stock has recorded a gain of 6.11%, while the performance over three months has reached 3.49%. Over a one-year horizon, the cumulative progression stands at 13.39%, reflecting a gradual recovery of the stock after a long period of weakness. The stock's beta is -0.11, indicating that it moves very weakly correlated—or even inversely—to the overall market. This characteristic can be explained by the small size of the market capitalization and the specific nature of Amoeba's business, which is focused on the niche segment of biological water treatment solutions and biocontrol. The volatility measured over one month is established at 8.08, a moderate level for a stock of this profile.
Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
Expected revenue: 1,5 millions d'euros
Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.